WST

SEC source: 0001127602-23-026551 · form4.xml · nonDerivative · entry 3

Witherspoon Charles · CIK 0001731739 · VP & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,431.091

SEC source: 0001127602-23-026551 · form4.xml · nonDerivative · entry 2

Witherspoon Charles · CIK 0001731739 · VP & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,025.091

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-23-026551 · form4.xml · nonDerivative · entry 1

Witherspoon Charles · CIK 0001731739 · VP & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,429.091

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-23-006659 · primarydocument.xml · derivative · entry 4

Favorite Annette F · CIK 0001654975 · Sr. VP & Chief HR Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,452

Underlying: Common Stock · 2,000 shares

Expires 2027-02-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This option is fully vested.

SEC source: 0001562180-23-006659 · primarydocument.xml · nonDerivative · entry 3

Favorite Annette F · CIK 0001654975 · Sr. VP & Chief HR Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,876.9617

F2 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $414.58 to $415.08, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

SEC source: 0001562180-23-006659 · primarydocument.xml · nonDerivative · entry 2

Favorite Annette F · CIK 0001654975 · Sr. VP & Chief HR Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,116.9617

F1 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $413.58 to $414.57, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

SEC source: 0001562180-23-006659 · primarydocument.xml · nonDerivative · entry 1

Favorite Annette F · CIK 0001654975 · Sr. VP & Chief HR Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,876.9617

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-23-006564 · primarydocument.xml · derivative · entry 7

Reiss-Clark Cindy · CIK 0001916513 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,756

Underlying: Common Stock · 1,112 shares

Expires 2030-02-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This award vests in four equal annual installments beginning on February 18, 2021.

SEC source: 0001562180-23-006564 · primarydocument.xml · derivative · entry 6

Reiss-Clark Cindy · CIK 0001916513 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,588

Underlying: Common Stock · 1,588 shares

Expires 2031-02-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This award vests in four equal annual installments beginning on February 23, 2022.

SEC source: 0001562180-23-006564 · primarydocument.xml · derivative · entry 5

Reiss-Clark Cindy · CIK 0001916513 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,331

Underlying: Common Stock · 777 shares

Expires 2032-02-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This award vests in four equal annual installments beginning on February 22, 2023.

SEC source: 0001562180-23-006564 · primarydocument.xml · nonDerivative · entry 4

Reiss-Clark Cindy · CIK 0001916513 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,320.1611

SEC source: 0001562180-23-006564 · primarydocument.xml · nonDerivative · entry 3

Reiss-Clark Cindy · CIK 0001916513 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,797.1611

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-23-006564 · primarydocument.xml · nonDerivative · entry 2

Reiss-Clark Cindy · CIK 0001916513 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,020.1611

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-23-006564 · primarydocument.xml · nonDerivative · entry 1

Reiss-Clark Cindy · CIK 0001916513 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,432.1611

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-23-006338 · primarydocument.xml · derivative · entry 13

Lai Quintin J · CIK 0001744326 · VP Strat & Investor Relations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,359

Underlying: Common Stock · 453 shares

Expires 2032-02-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: This award vests in four equal annual installments beginning on February 22, 2023.

SEC source: 0001562180-23-006338 · primarydocument.xml · derivative · entry 12

Lai Quintin J · CIK 0001744326 · VP Strat & Investor Relations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,388

Underlying: Common Stock · 1,388 shares

Expires 2031-02-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: This award vests in 4 equal annual installments beginning on 2/23/2022.

SEC source: 0001562180-23-006338 · primarydocument.xml · derivative · entry 11

Lai Quintin J · CIK 0001744326 · VP Strat & Investor Relations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,116

Underlying: Common Stock · 3,348 shares

Expires 2030-02-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: This award vests in four equal annual installments beginning on February 18, 2021.

SEC source: 0001562180-23-006338 · primarydocument.xml · derivative · entry 10

Lai Quintin J · CIK 0001744326 · VP Strat & Investor Relations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,140 shares

Expires 2029-02-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: This option is fully vested.

SEC source: 0001562180-23-006338 · primarydocument.xml · derivative · entry 9

Lai Quintin J · CIK 0001744326 · VP Strat & Investor Relations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,772 shares

Expires 2028-02-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: This option is fully vested.

SEC source: 0001562180-23-006338 · primarydocument.xml · nonDerivative · entry 8

Lai Quintin J · CIK 0001744326 · VP Strat & Investor Relations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,306.93

F3 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $395.97 to $396.45, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

SEC source: 0001562180-23-006338 · primarydocument.xml · nonDerivative · entry 7

Lai Quintin J · CIK 0001744326 · VP Strat & Investor Relations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,047.93

F2 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $394.97 to $395.93, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

SEC source: 0001562180-23-006338 · primarydocument.xml · nonDerivative · entry 6

Lai Quintin J · CIK 0001744326 · VP Strat & Investor Relations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,682.93

F1 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $393.97 to $394.96, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

SEC source: 0001562180-23-006338 · primarydocument.xml · nonDerivative · entry 5

Lai Quintin J · CIK 0001744326 · VP Strat & Investor Relations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,407.93

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-23-006338 · primarydocument.xml · nonDerivative · entry 4

Lai Quintin J · CIK 0001744326 · VP Strat & Investor Relations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,954.93

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-23-006338 · primarydocument.xml · nonDerivative · entry 3

Lai Quintin J · CIK 0001744326 · VP Strat & Investor Relations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,566.93

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-23-006338 · primarydocument.xml · nonDerivative · entry 2

Lai Quintin J · CIK 0001744326 · VP Strat & Investor Relations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,218.93

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-23-006338 · primarydocument.xml · nonDerivative · entry 1

Lai Quintin J · CIK 0001744326 · VP Strat & Investor Relations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,078.93

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-23-006299 · primarydocument.xml · derivative · entry 5

Witherspoon Charles · CIK 0001731739 · VP & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 708

Underlying: Common Stock · 840 shares

Expires 2029-02-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-23-006299 · primarydocument.xml · derivative · entry 4

Witherspoon Charles · CIK 0001731739 · VP & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,072

Underlying: Common Stock · 840 shares

Expires 2030-02-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-23-006299 · primarydocument.xml · nonDerivative · entry 3

Witherspoon Charles · CIK 0001731739 · VP & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,829.4979

SEC source: 0001562180-23-006299 · primarydocument.xml · nonDerivative · entry 2

Witherspoon Charles · CIK 0001731739 · VP & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,509.4979

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-23-006299 · primarydocument.xml · nonDerivative · entry 1

Witherspoon Charles · CIK 0001731739 · VP & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,669.4979

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-23-006276 · primarydocument.xml · derivative · entry 4

Abraham Silji · CIK 0001733001 · SVP, Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,160 shares

Expires 2029-02-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This option is fully vested.

SEC source: 0001562180-23-006276 · primarydocument.xml · nonDerivative · entry 3

Abraham Silji · CIK 0001733001 · SVP, Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,209.2997

SEC source: 0001562180-23-006276 · primarydocument.xml · nonDerivative · entry 2

Abraham Silji · CIK 0001733001 · SVP, Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,215.2997

F1 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $396.53 to $397.285, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

SEC source: 0001562180-23-006276 · primarydocument.xml · nonDerivative · entry 1

Abraham Silji · CIK 0001733001 · SVP, Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,369.2997

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-23-006265 · primarydocument.xml · derivative · entry 11

Green Eric Mark · CIK 0001336007 · Director · President & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 98,132

Underlying: Common Stock · 50,000 shares

Expires 2025-04-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · derivative.exercise_date: This option is fully vested.

SEC source: 0001562180-23-006265 · primarydocument.xml · nonDerivative · entry 10

Green Eric Mark · CIK 0001336007 · Director · President & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 140,574.0865

F2 · shares: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 5/5/2023. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. In total, 50,000 options were exercised with 44,000 shares sold and 6,000 shares held by the reporting person.

SEC source: 0001562180-23-006265 · primarydocument.xml · nonDerivative · entry 9

Green Eric Mark · CIK 0001336007 · Director · President & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 140,674.0865

F2 · shares: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 5/5/2023. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. In total, 50,000 options were exercised with 44,000 shares sold and 6,000 shares held by the reporting person.

F9 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $397.73 to $398.17, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

SEC source: 0001562180-23-006265 · primarydocument.xml · nonDerivative · entry 8

Green Eric Mark · CIK 0001336007 · Director · President & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 141,774.0865

F2 · shares: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 5/5/2023. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. In total, 50,000 options were exercised with 44,000 shares sold and 6,000 shares held by the reporting person.

F8 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $396.73 to $397.62, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

SEC source: 0001562180-23-006265 · primarydocument.xml · nonDerivative · entry 7

Green Eric Mark · CIK 0001336007 · Director · President & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 149,306.0865

F2 · shares: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 5/5/2023. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. In total, 50,000 options were exercised with 44,000 shares sold and 6,000 shares held by the reporting person.

F7 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $395.73 to $396.67, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

SEC source: 0001562180-23-006265 · primarydocument.xml · nonDerivative · entry 6

Green Eric Mark · CIK 0001336007 · Director · President & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 156,006.0865

F2 · shares: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 5/5/2023. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. In total, 50,000 options were exercised with 44,000 shares sold and 6,000 shares held by the reporting person.

F6 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $394.65 to $395.60, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

SEC source: 0001562180-23-006265 · primarydocument.xml · nonDerivative · entry 5

Green Eric Mark · CIK 0001336007 · Director · President & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 163,690.0865

F2 · shares: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 5/5/2023. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. In total, 50,000 options were exercised with 44,000 shares sold and 6,000 shares held by the reporting person.

F5 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $393.64 to $394.63, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

SEC source: 0001562180-23-006265 · primarydocument.xml · nonDerivative · entry 4

Green Eric Mark · CIK 0001336007 · Director · President & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 172,019.0865

F2 · shares: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 5/5/2023. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. In total, 50,000 options were exercised with 44,000 shares sold and 6,000 shares held by the reporting person.

F4 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $392.625 to $393.60, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

SEC source: 0001562180-23-006265 · primarydocument.xml · nonDerivative · entry 3

Green Eric Mark · CIK 0001336007 · Director · President & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 179,074.0865

F2 · shares: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 5/5/2023. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. In total, 50,000 options were exercised with 44,000 shares sold and 6,000 shares held by the reporting person.

F3 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $391.59 to $392.57, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

SEC source: 0001562180-23-006265 · primarydocument.xml · nonDerivative · entry 2

Green Eric Mark · CIK 0001336007 · Director · President & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 183,574.0865

F2 · shares: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 5/5/2023. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. In total, 50,000 options were exercised with 44,000 shares sold and 6,000 shares held by the reporting person.

SEC source: 0001562180-23-006265 · primarydocument.xml · nonDerivative · entry 1

Green Eric Mark · CIK 0001336007 · Director · President & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 184,574.0865

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in 2025, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 5/5/2023.

SEC source: 0001562180-23-006236 · primarydocument.xml · derivative · entry 6

Birkett Bernard · CIK 0001658001 · Sr VP, Chief Fin & Ops Off

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,884 shares

Expires 2028-06-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: This award vests over four years starting on the first anniversary date of the award.

SEC source: 0001562180-23-006236 · primarydocument.xml · derivative · entry 5

Birkett Bernard · CIK 0001658001 · Sr VP, Chief Fin & Ops Off

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,850

Underlying: Common Stock · 8,450 shares

Expires 2029-02-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This award vests in four equal annual installments beginning on February 19, 2020.

SEC source: 0001562180-23-006236 · primarydocument.xml · nonDerivative · entry 4

Birkett Bernard · CIK 0001658001 · Sr VP, Chief Fin & Ops Off

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,366

F2 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $371.00 to $371.05, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.